Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology
The DOI matches its Crossref record; 299 of the 300 references it cites were found in a registry or an index.
Abstract
Bile acids (BAs) can regulate their own metabolism and transport as well as other key aspects of metabolic homeostasis via dedicated (nuclear and G protein-coupled) receptors. Disrupted BA transport and homeostasis results in the development of cholestatic disorders and contributes to a wide range of liver diseases, including nonalcoholic fatty liver disease and hepatocellular and cholangiocellular carcinoma. Furthermore, impaired BA homeostasis can also affect the intestine, contributing to the pathogenesis of irritable bowel syndrome, inflammatory bowel disease, and colorectal and oesophageal cancer. Here, we provide a summary of the role of BAs and their disrupted homeostasis in the development of gastrointestinal and hepatic disorders and present novel insights on how targeting BA pathways might contribute to novel treatment strategies for these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional microbial metabolites, such as conjugated bile acids, can activate the farnesoid X receptor, suppressing hepatic stellate cell activation and fibrogenic signaling, thereby ameliorating liver fibrosis105,106.”
From Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming (2026) · cites this paper as [105]
In the citing paper
“Moreover, BAs have the potential to modulate the gut–brain axis by maintaining intestinal homeostasis, as TGR5 and FXR signaling are pivotal regulators of intestinal immune response and barrier function.365,376”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [376]
In the citing paper
“Peroxisome proliferator-activated receptors (PPARs), liver X receptors (LXRs), FXR and THR (particularly THR-β) are the most extensively studied receptors that are targets for therapy.20–22”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [20]
Citations
Cites
Changes of Intestinal Functions in Liver Cirrhosis
Fukui, H., & Wiest, R. (2016) · Inflammatory Intestinal Diseases · doi:10.1159/000444436 · Cited by 6,808
Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Cited by
Items 201–300 of 537
Wang, J., Ma, L., An, Y., Ge, Y., Xu, D., & Mao, E. (2025) · Pharmaceuticals · doi:10.3390/ph18050763 · Cited by 11
Xun, Z., Yao, X., Lin, C., Yang, X., Zhang, Y., Yang, X., He, Y., Jiang, R., Lan, Y., Ye, Y., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101456 · Cited by 10
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
Chrysavgis, L., Mourelatou, N. G., & Cholongitas, Ε. (2025) · Biomedicines · doi:10.3390/biomedicines13071516 · Cited by 10
Dong, Q., Wang, Y., He, Y., Gao, T., Li, L., Chen, L., Liu, C., Wang, W., Liu, X., Zhang, Y., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120269 · Cited by 10
The particle drifting effect in vivo: impact of dose and animal species
Sharma, M., Yang, D. H., Adhikari, S., Lin, X., Lü, X., & Li, N. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126060 · Cited by 10
Ma, H., Wu, Y., Li, D., Sun, H., Xie, Y., Zhao, S., Guo, W., Wang, M., Cui, R., Huang, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.006 · Cited by 11
Cai, X., Sun, T., Mengzhen, F. E. N. G., Chen, G. M., Zhou, J., Zhuang, H., Wang, D., Chen, Y., Cheng, Z., Xu, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202508693 · Cited by 10
Shou, J., & Fu, T. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2665890 · Cited by 10
Zhi, Y., Dong, Y., Li, X., Zhong, W., Lei, X., Tang, J. T., & Mao, Y. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3846 · Cited by 10
Hu, Y., Sang, N., Wu, A., Pu, J., Yan, H., Luo, J., Zheng, P., Luo, Y., Yu, J., He, J., et al. (2025) · Animal nutrition · doi:10.1016/j.aninu.2024.12.003 · Cited by 10
Yang, Y., Jiao, L., Guo, F., Sun, Y., Cui, H., Lei, X., Hu, J., & Wan, Y. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.4c07569 · Cited by 10
Caicedo, K. Y. O., Fernández-Materán, F. V., Daniel, S. L., Anantharaman, K., Ridlon, J. M., & Alves, J. M. P. (2025) · Microorganisms · doi:10.3390/microorganisms13040857 · Cited by 10
Roumain, M., & Muccioli, G. G. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100697 · Cited by 9
Liao, L., Liu, Z., Liu, L., Huang, C., Li, Y., Mao, C., Xu, R., Liu, H., Liu, C., Peng, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57330-7 · Cited by 9
Li, X., Huang, X., Song, K., Liu, J., Jin, Y., Li, T., Zhang, L., & Zhang, H. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156691 · Cited by 9
Zhang, C., Sun, G., Jin, H., Wei, Y., Zheng, S., Wang, X., Zhao, X., Zhang, D., & Jia, J. (2025) · BMC Medicine · doi:10.1186/s12916-025-04043-9 · Cited by 9
Xu, J., Luo, Y., Lu, F., Xu, X., Jiang, C., Kang, M., Chang, C., Wei, H., Long, T., Jiang, B., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115471 · Cited by 9
Taming fatty liver: can taurine combat metabolic dysfunction in MASLD?
Meng, L., Lu, F., Zhang, B., Ma, Y., & Gao, J. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02439-x · Cited by 9
Sun, X., Wang, C., Liu, X., Li, Y., Ren, Z., Yang, X., & Liu, Y. (2025) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-025-01280-z · Cited by 9
Leng, L., Zhou, G., Liu, A., Wang, H., & Ni, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311530 · Cited by 9
Pharmacology and therapeutics of bile acid synthesis and modification enzymes in metabolic diseases
Ding, L., Jin, L., & Huang, W. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100115 · Cited by 9
Du, Z., Yin, S., Liu, B., Zhang, W., Sun, J., Fang, M., Xu, Y., Hua, K., Tu, P., Zhang, G., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16083 · Cited by 9
Yu, T., Yan, J., Wang, R., Zhang, L., Hu, X., Xu, J., Li, F., & Sun, Q. (2024) · Antioxidants · doi:10.3390/antiox13020214 · Cited by 9
Wang, B., Zhou, A., Wu, Y., Pan, Q., Wei, X., Gao, Y., Xiao, W., Jin, J., Zhou, T., Luo, Y., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001671 · Cited by 10
Bayoude, A., Zhang, J., Shen, Y., Tilyek, A., & Chai, C. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119400 · Cited by 9
Xu, Y., Chen, Y., Zhang, J., Wang, J., Yang, S., Zhao, H., Wu, L., Lei, J., Zhou, Y., Peng, J., et al. (2025) · Advanced Science · doi:10.1002/advs.202411888 · Cited by 9
Liu, X., Sun, H., Han, Q., Wang, Z., Zeng, J., Liu, J., Ou, S., Jin, K., Shao, Y., Li, D., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114471 · Cited by 9
Gut microbiota as a metabolic mediator to prevent or attenuate MASLD
Luo, J., Wei, Y., Fan, Z., Li, B., Li, L., Chai, Y., Xing, Z., Qiu, Y., Lu, W., & Fang, Z. (2025) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2025.2545525 · Cited by 9
Qu, K., Zeng, J., Deng, J., Dong, X., Liu, H., Zhang, S., Chi, S., Qihui, Y., Tan, B., & Xie, S. (2025) · Aquaculture · doi:10.1016/j.aquaculture.2025.742562 · Cited by 8
Li, T., & Jing, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1565778 · Cited by 8
Kim, E. Y., & Lee, J. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125825 · Cited by 8
Nie, Y., Shi, Y., & Yang, Y. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00212 · Cited by 8
Liú, Y., Geng, H., Han, B., Song, K., Li, J., Ji, S., Xue, J., & Zhang, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147096 · Cited by 8
Iridoids in gardenia fruit: key components in liver disease therapy
Cao, Q., Du, X., Liu, A. A., Li, Q. H., Luo, Q., Chen, Y., Wang, R., & Meng, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1667863 · Cited by 8
Yoon, G., Kim, S. J., & Jang, J. (2025) · International Journal of Precision Engineering and Manufacturing · doi:10.1007/s12541-025-01362-y · Cited by 8
Intestinal TGR5-targeted carrier-drug conjugate improves glycemic control in mice and pigs
Zhang, Y., Huang, H., Wang, Y., Li, X., Hou, P., Yu, M., Zhang, Z., Guo, S., Liu, C., Zhang, Z., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado5177 · Cited by 8
Bile acids and gut microbiota: interactions and impacts on polycystic ovary syndrome
Qian, H., Tao, J., Shi, L., Haiyan, S., Yang, L., Cui, L. J., Xu, W., & Wang, L. (2026) · Frontiers in Microbiomes · doi:10.3389/frmbi.2025.1702198 · Cited by 8
Advances in research on the effects of bile acids and their receptors on intestinal function
Cheng, Y., Zhang, L., Zhang, M., & Yu, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1821418 · Cited by 8
Molecular mechanisms and pathogenesis of MASH
Gallage, S., Govaere, O., Anstee, Q. M., Shulman, G. I., Tacke, F., & Heikenwälder, M. F. (2026) · Nature · doi:10.1038/s41586-026-10529-0 · Cited by 10
Waldner, B. J., Aldrian, D., Zöggeler, T., Oberacher, H., Oberhuber, R., Schneeberger, S., Messner, F., Schneider, A.-M., Kohlmaier, B., Lanzersdorfer, R., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000151 · Cited by 8
Secondary bile acids are associated with body lipid accumulation in obese pigs
Hu, Y., Wu, A., Yan, H., Pu, J., Luo, J., Zheng, P., Luo, Y., Yu, J., He, J., Yu, B., et al. (2024) · Animal nutrition · doi:10.1016/j.aninu.2024.04.019 · Cited by 8
Bile acids promote lipopolysaccharide clearance via the hepato-biliary pathway in broiler chickens
Chen, L., Ma, S., Cao, A., & Zhao, R. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116767 · Cited by 8
Dynamic pattern of postprandial bile acids in paediatric non‐alcoholic fatty liver disease
Huang, J., Lin, H., Liu, A., Wu, W., Alisi, A., Loomba, R. S., Xu, C., Xiang, W., Shao, J., Dong, G., et al. (2024) · Liver International · doi:10.1111/liv.16054 · Cited by 8
Deng, Y., Wang, J., Wu, D., Qin, L., He, Y., & Tan, D. (2024) · Molecules · doi:10.3390/molecules29174080 · Cited by 8
Silybin Meglumine Mitigates CCl4-Induced Liver Fibrosis and Bile Acid Metabolism Alterations
Liu, X., Xia, N., Yu, Q., Jin, M., Wang, Z., Fan, X., Zhao, W., Li, A., Jiang, Z., & Zhang, L. (2024) · Metabolites · doi:10.3390/metabo14100556 · Cited by 8
Shang, X. C., Fu, Y., Wang, Y., & Yan, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1506430 · Cited by 8
Pang, F., Jiang, Q., Li, K., & Tang, X. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156631 · Cited by 8
The liver-gut axis perspective: Exploring the pathogenesis of fatty liver
Yang, Z., Zhang, J., Liu, X., Chen, H., Duan, H., Wang, Q., Zhao, W., & Jin, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177822 · Cited by 8
Apical bulkheads accumulate as adaptive response to impaired bile flow in liver disease
Mayer, C., Nehring, S., Kücken, M., Repnik, U., Seifert, S., Sljukic, A., Delpierre, J., Morales-Navarrete, H. A., Hinz, S., Brosch, M., et al. (2023) · EMBO Reports · doi:10.15252/embr.202357181 · Cited by 9
de Bruijn, V. M. P., Kronnie, W. T., Rietjens, I. M. C. M., & Bouwmeester, H. (2023) · ALTEX · doi:10.14573/altex.2302011 · Cited by 8
Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway
Zhou, C., Pan, X., Huang, L., Wu, T., Zhao, T., Qi, J., Wu, J., Mukondiwa, A. V., Tang, Y., Luo, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166870 · Cited by 8
Qu, Y., Gong, X., Zhao, Z., Zhang, Z., Zhang, Q., Huang, Y., Xie, Q., Liu, Y., Wei, J., & Du, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020919 · Cited by 8
Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study
Guerrero, L., Carmona‐Rodríguez, L., Santos, F. M., Ciordia, S., Aroeira, L. S., Hierro, L., Pérez‐Montero, P., Vicent, D., & Corrales, F. J. (2024) · BioFactors · doi:10.1002/biof.2041 · Cited by 8
Avcioglu, S. Y., & Berkel, Ç. (2025) · Apmis · doi:10.1111/apm.70066 · Cited by 7
Fu, Y., Xu, B., Qin, W., Xiao, W., Huang, H., Hu, J., Cui, M., Mei, Q., Fan, J., Huang, C., et al. (2026) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2026.101732 · Cited by 7
Wen, Y., Zhang, T., Zhang, B., Wang, F., Wei, X., Wei, Y., Ma, X., & Tang, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27819 · Cited by 8
Yang, H., Yang, T., Ding, J., Wang, X., Chen, X., Liu, J., Shu, T., Wu, Z., Sun, L., Huang, X., et al. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4669 · Cited by 7
Niu, D., Wu, X., Zhang, Y., Wang, X., Chan, D. S., Jing, S., Wong, C., Wang, W., & Leung, C. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.10.028 · Cited by 7
Wu, X., Qiao, Y., Hou, Y., Zhang, X., Ocholi, S. S., Wang, L., Yan, Z., Li, J., & Han, L. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116734 · Cited by 7
Advances of exosome regulating‑FXR to repair inflammatory bowel disease (Review)
Muro, P., Jing, C., Qiao, Y., Wang, W., Wang, B., & Mao, F. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5576 · Cited by 7
Liao, M., Dong, H., Chen, G., Li, W., & Li, G. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1658493 · Cited by 7
Watling, C. Z., Petrick, J. L., Graubard, B. I., Zhang, X., Barnett, M. J., Buring, J. E., Chen, Y., Eliassen, A. H., Gaziano, J. M., Hofmann, J. N., et al. (2025) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaf086 · Cited by 8
Hu, Y., Lin, C., Zhang, L., Jiang, X., Li, H., & Wu, Y. (2026) · Advanced Science · doi:10.1002/advs.202523582 · Cited by 8
Featuring molecular regulation of bile acid homeostasis in pediatric short bowel syndrome
Mutanen, A., & Pakarinen, M. P. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102220 · Cited by 7
Li, H., Guo, X., Liu, X., Zhao, J., Chen, W., & Yang, B. K. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.105326 · Cited by 7
Tang, S., Yan, G., Kong, L. D., Sun, H. J., Liu, C., Han, Y. M., & Wang, X. (2025) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000160 · Cited by 7
Somabattini, R. A., Sherin, S., Siva, B., Chowdhury, N., & Nanjappan, S. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122806 · Cited by 8
Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming
Zhang, W., Song, S., Zhang, Y., Pan, Y., Hu, D., & Wang, Y. (2026) · npj Aging · doi:10.1038/s41514-026-00355-z · Cited by 6
“Additional microbial metabolites, such as conjugated bile acids, can activate the farnesoid X receptor, suppressing hepatic stellate cell activation and fi brogenic signaling, thereby amelioratingliver fi brosis 105,106 .”
The Effect of MSTN Mutation on Bile Acid Metabolism and Lipid Metabolism in Cattle
Wu, D., Wang, S., Hai, C., Wang, L., Pei, D., Bai, C., Su, G., Liu, X., Zhao, Y., Liu, Z. H., et al. (2023) · Metabolites · doi:10.3390/metabo13070836 · Cited by 6
Rosatelli, E., Carotti, A., Cerra, B., Franco, F., Passeri, D., Pellicciari, R., & Gioiello, A. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115851 · Cited by 6
Wei, P., Sun, W., Hao, S., Deng, L., Zou, W., Wu, H., Lü, W., & He, Y. (2024) · Animals · doi:10.3390/ani14152198 · Cited by 6
Zhao, Z., Wang, B., Jiang, K., Liu, M., & Wang, L. (2024) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2024.109920 · Cited by 6
Pan, S., Yan, H., Zhu, J., Ma, Y., Wang, P., Liu, Y., & Chen, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1476407 · Cited by 7
Xie, Y., Li, Z., Fan, Y., Liu, X., Yi, R., Gan, Y., Yang, Z., & Liu, S. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156201 · Cited by 6
Zhang, J., Wang, Q., Zhou, N., Liu, J., Tao, L., Peng, Z., Hu, G., Wang, H., Fu, L., & Peng, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-94401-7 · Cited by 6
Wu, D., Liu, J., Guo, Z., Wang, L., Yao, Z., Wu, Q., Lu, Y., & Lv, W. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114708 · Cited by 6
Peng, Z., Deng, J., Xu, Z.-J., Niu, Q.-J., Lamesgen, D., Refaie, A., Sun, L., Feng, Y., & Liu, M. (2025) · Toxicon · doi:10.1016/j.toxicon.2025.108419 · Cited by 6
Miyah, Y., Benjelloun, M. C., Omari, H. E., El-Mouhdi, K., & Feniche, M. E. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100839 · Cited by 6
Bayne, J. E., Charavaryamath, C., Hu, Y., Yousefi, F., Murphy, M., Law, A., Michael, A., Muyyarikkandy, M. S., Nibbering, B., Smits, W. K., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2568706 · Cited by 6
Lü, H., Luo, H., Li, P., Yang, Y., Cao, S., Zhang, Y., Ma, H., Zhao, Q., Zheng, Y., & Wang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1705635 · Cited by 6
Wu, W., Wang, S., Xue, C., & Dong, N. (2026) · Animal nutrition · doi:10.1016/j.aninu.2025.10.004 · Cited by 7
Bile acids as gatekeepers: Orchestrating gut-liver axis for metabolic and immune balance
Chen, Q., Xin, L. I. U., & Jiang, Z.-H. (2026) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2026.01.001 · Cited by 6
Liu, J., Elsheikha, H. M., Lei, C.-C., Qin, S., Liu, Y., Ni, H.-B., Qin, Y., Yu, H.-L., Su, J.-W., Chen, B.-N., et al. (2026) · BMC Microbiology · doi:10.1186/s12866-026-04750-0 · Cited by 6
Li, Y. C., Hu, Y., He, Y. M., Yang, Y., Xue, D., Xue, E., Jia, J., Zhang, W., & Wang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1793092 · Cited by 6
Basri, R., Al‐kuraishy, H. M., Alruwaili, M., Al-Gareeb, A. I., Albuhadily, A. K., Alexiou, A. T., Papadakis, M., Faheem, S. A., & Batiha, G. E. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05516-1 · Cited by 6
Song, K., Liang, D., Xiao, D., Kang, A., & Ren, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13323 · Cited by 6
MAPL loss dysregulates bile and liver metabolism in mice
Goyon, V., Besse‐Patin, A., Zunino, R., Ignatenko, O., Nguyen, M., Coyaud, É., Lee, J. M., Nguyen, B., Raught, B., & McBride, H. M. (2023) · EMBO Reports · doi:10.15252/embr.202357972 · Cited by 6
Magnesium and LongevityPreprint
Chambers, P. W. (2024) · Qeios · doi:10.32388/n1scbr.2 · Cited by 6
Tenascin C-Guided Nanosystem for Precision Delivery of Obeticholic Acid in Liver Fibrosis Therapy
Wang, Y., Yang, L., Xu, Q., Liu, T., He, H., Liu, L., & Yin, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010032 · Cited by 5
Goyzueta-Mamani, L. D., Lage, D. P., Barazorda-Ccahuana, H. L., Paco-Chipana, M., Candia-Puma, M. A., Dávila-Del-Carpio, G., Galdino, A. S., Machado‐de‐Ávila, R. A., Giunchetti, R. C., D'Antonio, E. L., et al. (2025) · Molecules · doi:10.3390/molecules30010173 · Cited by 5
Sleem, I., Rodriguez, A., Chen, B., Perumal, R., Peterson, J., Santana, Á. L., Smolensky, D., & Día, V. P. (2025) · BioFactors · doi:10.1002/biof.70028 · Cited by 5
Xu, Y., Zhang, F., Ke, Z., Lin, Y., Zhang, Y., Liu, Y., Zhang, Y. Y., Xu, J., & Liu, Y. (2025) · Liver International · doi:10.1111/liv.70130 · Cited by 5
Li, X., Qiu, H., Li, W., van Gestel, C. A. M., Jin, C., & He, E. (2025) · Environment International · doi:10.1016/j.envint.2025.109670 · Cited by 5
Apodaka‐Biguri, M., Simão, A. L., González‐Romero, F., Mestre, D., Rodrigues, P. M., Aurrekoetxea, I., Gómez‐Santos, B., Buqué, X., Nieva‐Zuluaga, A., de Gauna, M. R., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001461 · Cited by 5
Wang, C., Liu, S., Gao, C., Dai, X., Lian, L., Cui, Z., Nan, J., & Wu, Y. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120537 · Cited by 5
Luo, X., Mao, T., Wang, X., Cheng, P., Liu, M., Tao, R., Wang, F., Zhao, L., Shan, Y., Lu, Y., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00862-z · Cited by 5
Xu, F.-P., Yang, C., Yu, S., Cai, H., Hui, M.-Y., Fang, L., Chen, G., Jiang, S., Qi, S.-L., Wu, S.-J., et al. (2026) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2026.03.003 · Cited by 6
Zhang, F., Liu, R., Xu, T., Xu, W., Huang, K., & He, X. (2026) · Nutrients · doi:10.3390/nu18060953 · Cited by 5
Zhang, L., Zhu, L.-L., Zhu, X., Fu, S., & Liu, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1337057 · Cited by 5
Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis
Hofer, B., Simbrunner, B., Königshofer, P., Brusilovskaya, K., Petrenko, O., Țâru, V., Sorz, T., Zinober, K., Semmler, G., Kauschke, S. G., et al. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.09.006 · Cited by 5
Self-citation
Metadata
- Authors
- Fuchs, C. D., & Trauner, M.
- Affiliations
- Medical University of Vienna (AT)
- Corresponding author
- Trauner, Michael
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2022-02-14
- Volume
- 19
- Issue
- 7
- Pages
- 432-450
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W4212954224
- Cited by
- 490
- References
- 300
- Citations by year
- 2026: 134 · 2025: 145 · 2024: 111 · 2023: 77 · 2022: 23
- FWCI
- 10.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- bile acids, bile acid receptors, nuclear receptors, G protein-coupled receptors, bile acid homeostasis, bile acid transport, cholestasis, non-alcoholic fatty liver disease, hepatocellular carcinoma, cholangiocarcinoma, irritable bowel syndrome, inflammatory bowel disease, colorectal cancer, esophageal cancer
- MeSH terms
- Bile Acids and Salts, Cholestasis, Homeostasis, Humans, Liver, Receptors, G-Protein-Coupled, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.